Saturday 17 October 2026
Export CLDI’s income statement to Excel — free account
Calidi Biotherapeutics, Inc.
CLDI Healthcare Biotechnology
Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00. In the quarter to June 2026, EPS grew 90.8%, free cash flow grew 11.2% and total debt fell 7.87%, each against the same quarter a year earlier.
0.84
0.03
−3.45%
Follow CLDI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 18,679.68 | 18,816.00 | 2,630.40 | 140.16 | 17.60 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 19,737.60 | 20,256.00 | 26,476.80 | 3,225.60 | 307.20 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 2 | 2 | 41 | 28 | 29 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | 68.89 | — | — | — | |||||
| EBT | — | — | — | — | — | 3 | (25) | (29) | (22) | (20) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | (56,480.00) | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | — | 3 | (25) | (29) | (22) | (20) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 10.23 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | 1,131.33 | (5,742.43) | (3,322.93) | (570.47) | (95.20) | |||||
| Cash flow | — | — | — | — | — | (360.97) | (3,003.18) | (3,066.25) | (472.28) | (79.19) | |||||
| Capex | — | — | — | — | — | 0.00 | (97.27) | (66.48) | (0.38) | (0.45) | |||||
| Free cash flow | — | — | — | — | — | (360.97) | (3,100.45) | (3,132.73) | (472.66) | (79.63) | |||||
| Book value | — | — | — | — | — | (4,895.60) | (11,463.64) | (935.80) | 47.19 | 13.98 | |||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| P/B | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | (6.52) | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (13) | (27) | (20) | (21) | ||||
| Capex | — | — | — | — | — | — | 0 | (1) | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | (1) | (14) | (28) | (20) | (21) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | (42) | (6) | 1 | 2 | ||||
| Total debt | — | — | — | — | — | — | 1 | 2 | 1 | 1 | |||||
| Net debt | — | — | — | — | — | (1) | 1 | 0 | (9) | (5) | |||||
| Shareholders’ equity | — | — | — | — | — | (15) | (50) | (8) | 2 | 4 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 2.92 | (21.70) | (463.16) | (196.80) | (222.05) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.00 | 78.08 | 99.59 | 759.98 | (893.28) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022
Charts ten years each
Calidi Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.3M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CLDI Calidi Biotherapeutics, Inc. | $3.2M | — (loss-making) | — | — | n/m | +11.16% (above 0%: growing) | — | 0.00% | |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.2M | — (loss-making) | — (loss-making) | −100.78% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| EOCN Eocene Ltd. | $3.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −67.74% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| APVO Aptevo Therapeutics Inc. | $3.1M | 0.0× | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.1M | 0.0× | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $3.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $3.2M | — | — | −66.24% | — | −19.01% | 0.00% | 0.00% |
Calidi Biotherapeutics, Inc. (CLDI) key facts
- Calidi Biotherapeutics, Inc. (CLDI) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00.
- As of October 16, 2026, CLDI traded at $0.84, a market capitalization of $3.2 million.
- Return on equity was −893.3% and debt-to-equity 0.24.
- Its Altman Z-score is −85.83 (distress zone) for fiscal 2022.